Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
We report the case of a young woman with HER2-positive advanced breast cancer, arising during pregnancy, with visceral involvement at onset, treated with third line therapy with the combination lapatinib and capecitabine resulting in a nearly complete long-term tumor response . The patient had prev...
Main Author: | Michela Donadio |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2018-06-01
|
Series: | AboutOpen |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/55 |
Similar Items
-
Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer
by: Maria Moritti, et al.
Published: (2018-06-01) -
Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01) -
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01) -
Long-term survival in a young woman with recurrent HER2-positive breast cancer.
by: Gianluca Cotroneo
Published: (2018-06-01) -
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
by: Fan Yang, et al.
Published: (2020-03-01)